Kantaro

Founded in New York City during the initial COVID-19 outbreak, Kantaro Biosciences (“Kantaro”) is a joint venture between Mount Sinai and RenalytixAI, to drive rapid innovation and scale-up of rigorous, results-driven and reproducible diagnostic tests for critical health challenges. Kantaro’s groundbreaking antibody test, based on technology developed at Mount Sinai and manufactured in partnership with Bio-Techne, is the one of the first tests capable of identifying the level of an individual’s neutralizing antibodies.

Inspired by the shape of the antibodies, the logo symbol is made out of the antibodies joining together to form a circle to represent the dedication and focus of Kantaro's innovation. The antibody graphic is also activated throughout the system to create flexible patterns and icons.